BR112023002703A2 - Métodos para tratar angioedema hereditário, para induzir a remissão sustentada de hae, para prevenir ataques de angioedema, para reduzir o risco de ataques de angioedema e para reduzir o risco de desenvolver ataques de angioedema, composições farmacêuticas e kit - Google Patents

Métodos para tratar angioedema hereditário, para induzir a remissão sustentada de hae, para prevenir ataques de angioedema, para reduzir o risco de ataques de angioedema e para reduzir o risco de desenvolver ataques de angioedema, composições farmacêuticas e kit

Info

Publication number
BR112023002703A2
BR112023002703A2 BR112023002703A BR112023002703A BR112023002703A2 BR 112023002703 A2 BR112023002703 A2 BR 112023002703A2 BR 112023002703 A BR112023002703 A BR 112023002703A BR 112023002703 A BR112023002703 A BR 112023002703A BR 112023002703 A2 BR112023002703 A2 BR 112023002703A2
Authority
BR
Brazil
Prior art keywords
angioedema
risk
attacks
reduce
methods
Prior art date
Application number
BR112023002703A
Other languages
English (en)
Inventor
Wolfe Jia
Gaspar Bobby
Lemoine Adrien
Simeon Marks-Bluth Jonathon
Sagoo Pervinder
Pennucci Valentina
Original Assignee
Orchard Therapeutics Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orchard Therapeutics Europe Ltd filed Critical Orchard Therapeutics Europe Ltd
Publication of BR112023002703A2 publication Critical patent/BR112023002703A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

MÉTODOS PARA TRATAR ANGIOEDEMA HEREDITÁRIO, PARA INDUZIR A REMISSÃO SUSTENTADA DE HAE, PARA PREVENIR ATAQUES DE ANGIOEDEMA, PARA REDUZIR O RISCO DE ATAQUES DE ANGIOEDEMA E PARA REDUZIR O RISCO DE DESENVOLVER ATAQUES DE ANGIOEDEMA, COMPOSIÇÕES FARMACÊUTICAS E KIT. Trata-se de composições e métodos para tratar um sujeito com ou em risco de desenvolver angioedema hereditário. Com o uso das composições e dos métodos da divulgação, um paciente pode receber um ou mais agentes que elevam os níveis de expressão e/ou atividade do inibidor de C1-esterase (C1-INH). Os agentes exemplificativos que podem ser usados em conjunto com as composições e os métodos da divulgação para essa finalidade incluem células, como células pluripotentes, que expressam C1-INH.
BR112023002703A 2020-08-14 2021-08-13 Métodos para tratar angioedema hereditário, para induzir a remissão sustentada de hae, para prevenir ataques de angioedema, para reduzir o risco de ataques de angioedema e para reduzir o risco de desenvolver ataques de angioedema, composições farmacêuticas e kit BR112023002703A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063066011P 2020-08-14 2020-08-14
PCT/US2021/045881 WO2022036179A2 (en) 2020-08-14 2021-08-13 Compositions and methods for treating or preventing hereditary angioedema

Publications (1)

Publication Number Publication Date
BR112023002703A2 true BR112023002703A2 (pt) 2023-04-25

Family

ID=80248196

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002703A BR112023002703A2 (pt) 2020-08-14 2021-08-13 Métodos para tratar angioedema hereditário, para induzir a remissão sustentada de hae, para prevenir ataques de angioedema, para reduzir o risco de ataques de angioedema e para reduzir o risco de desenvolver ataques de angioedema, composições farmacêuticas e kit

Country Status (10)

Country Link
US (1) US20230313227A1 (pt)
EP (1) EP4196172A2 (pt)
JP (1) JP2023540877A (pt)
KR (1) KR20230110243A (pt)
AU (1) AU2021324891A1 (pt)
BR (1) BR112023002703A2 (pt)
CA (1) CA3191729A1 (pt)
IL (1) IL300568A (pt)
MX (1) MX2023001764A (pt)
WO (1) WO2022036179A2 (pt)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070093443A1 (en) * 2005-10-21 2007-04-26 Madison Edwin L Modified proteases that inhibit complement activation

Also Published As

Publication number Publication date
CA3191729A1 (en) 2022-02-17
AU2021324891A8 (en) 2023-04-27
MX2023001764A (es) 2023-04-25
WO2022036179A2 (en) 2022-02-17
WO2022036179A3 (en) 2022-03-24
IL300568A (en) 2023-04-01
AU2021324891A1 (en) 2023-04-06
EP4196172A2 (en) 2023-06-21
JP2023540877A (ja) 2023-09-27
US20230313227A1 (en) 2023-10-05
KR20230110243A (ko) 2023-07-21
AU2021324891A9 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
Murphy et al. Ca2+‐dependent proteolysis of junctophilin‐1 and junctophilin‐2 in skeletal and cardiac muscle
Jagasia et al. Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis
BR112021019722A2 (pt) Compostos de piperidina 3-substituídos para inibição de cbl-b, e uso de inibidor de cbl-b em combinação com vacina contra câncer e/ou vírus oncolítico
BR112021026241A2 (pt) Compostos de benzil-triazol substituído para inibição de cbl-b e outros usos dos mesmos
BR112021015098A2 (pt) Inibidores de enpp1 e métodos de modulação da resposta imune
NO20072654L (no) Cancer behandling
BR112017020973A2 (pt) método para tratar câncer em um paciente
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
BRPI0517135A (pt) composições e métodos para tratar doenças neoplásticas
BRPI0622054B8 (pt) composto e composição farmacêutica
BRPI0617165B1 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
BR112022020817A2 (pt) Inibidores de kif18a para tratamento de doenças neoplásicas
BR112018001533A2 (pt) método de redução da necessidade de cirurgia em pacientes sofrendo da hiperplasia benigna da próstata
GT200600254A (es) Moduladores de aminoquinolina y aminoquinazolina quinasa
BR112023009531A2 (pt) Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos
BR112023001956A2 (pt) Composto de fórmula (ia), (ib), (ic) ou (ii), composição farmacêutica, composto para uso ou composição farmacêutica para uso em um método de tratamento de câncer
Struthers et al. Allopurinol: novel indications in cardiovascular disease
BR112021012654A2 (pt) Métodos de tratamento de infecções por tempestade de citocina, incluindo covid-19, através da inibição da interação ccr5/ccl5 (rantes) e composições para a prática da mesma
BR112012005670A2 (pt) ''método para a identificação de um paciente com câncer que pode se beneficiar com a terapia antiagiogênica, método para a predição da responsividade de um paciente com câncer à terapia antiangiogênica, uso de um anticorpo anto- vegf para melhorar o efeito do tratamento de um paciente sofrendo de câncer, método ou uso, kit útil para realizar o método, uso de uma proteína ou usom kit útil para realizar o método, uso de uma proteína ou oligonucleotídeo ou matriz de polinecleotídeo para determinar o nível de expressão de bfgf em um método e kit ou uso
Kunkel et al. Mechanisms of TFAM-mediated cardiomyocyte protection
Yetik-Anacak et al. Resveratrol stimulates hydrogen sulfide (H2S) formation to relax murine corpus cavernosum
BR112022021910A2 (pt) Inibidores da proteína bcl-2
Al‐Kafaji et al. Time‐course effect of high‐glucose‐induced reactive oxygen species on mitochondrial biogenesis and function in human renal mesangial cells
BRPI0608061A2 (pt) método para abaixar os nìveis no sangue circulante de um lipìdio selecionado do grupo que consiste em colesterol ldl, triglicerìdios, colesterol total, e as misturas destes e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons
BR112023002703A2 (pt) Métodos para tratar angioedema hereditário, para induzir a remissão sustentada de hae, para prevenir ataques de angioedema, para reduzir o risco de ataques de angioedema e para reduzir o risco de desenvolver ataques de angioedema, composições farmacêuticas e kit